Day One Biopharmaceuticals Inc

NASDAQ DAWN

Download Data

Day One Biopharmaceuticals Inc Book Value Per Share 5 year CAGR for the year ending December 31, 2023

Day One Biopharmaceuticals Inc Book Value Per Share 5 year CAGR is NA for the year ending December 31, 2023. The book value per share represents the net value of a company allocated to each outstanding share of common stock. It is calculated by dividing shareholders' equity by the weighted average number of shares outstanding. The book value per share provides insight into the intrinsic value of a company's shares and can be used to assess the relative value of a stock compared to its market price. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Day One Biopharmaceuticals Inc Book Value Per Share for the year ending December 31, 2022 was -4.12, a -100.17% change year over year.
  • Day One Biopharmaceuticals Inc Book Value Per Share for the year ending December 31, 2021 was -2.06, a -135.11% change year over year.
  • Day One Biopharmaceuticals Inc Book Value Per Share for the year ending December 31, 2020 was -0.88, a -244.69% change year over year.
  • Day One Biopharmaceuticals Inc Book Value Per Share for the year ending December 31, 2019 was -0.25.
NASDAQ: DAWN

Day One Biopharmaceuticals Inc

CEO Dr. Jeremy Bender M.B.A., Ph.D.
IPO Date May 27, 2021
Location United States
Headquarters 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees 174
Sector Healthcare
Industry Biotechnology
Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email